Submit an abstract by August 5 for the AACR Special Conference on Tumor Immunology and Immunotherapy (October 18-21, Boston), chaired by Yvonne Y. Chen, Sergio Quezada, Robert D. Schreiber, and Fernando Vidal-Vanaclocha. Learn more: https://bit.ly/4ffuU2f #AACRtii24
American Association for Cancer Research’s Post
More Relevant Posts
-
🔬 Elevate Your Cancer Research with the ddPCR Microsatellite Instability (MSI) Kit! The ddPCR Microsatellite Instability (MSI) Kit provides sensitive, reproducible, qualitative results. Uncover deletions and insertions in mononucleotide microsatellite markers with utmost precision in plasma or tumor tissue samples. Features and benefits include: ✅ Explore MSI markers using both FFPE and plasma samples – a versatile solution at your fingertips. ✅ Bid farewell to the need for normal tissue samples – streamline your research like never before. ✅ Embrace enhanced workflow and cost efficiency, outshining current methods. ✅ Immerse yourself in automated data analysis, customizable to your preferences. ✅ Achieve unparalleled concordance with gold standard IHC and PCR-CE methods. Your breakthrough moments await. Discover more: https://ow.ly/UJ0t50PXM0U #CancerResearch #ddPCRMSIKit
To view or add a comment, sign in
-
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma A discussion on our recent study: In a new article now online, David Aggen & Jonathan Rosenberg discuss the intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma. https://lnkd.in/eBpHjMWJ
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma - Nature Reviews Clinical Oncology
nature.com
To view or add a comment, sign in
-
🎖️Today we share the Editor's Choice #Article "Immune Checkpoint Inhibitors—Associated Cardiotoxicity" 🧐by Chenghui Li et al. UAMS - University of Arkansas for Medical Sciences 📌Link here: https://lnkd.in/dVTbWej9 🔆Editor comment: Despite of evidence of the high response rate of immune checkpoint inhibitors (ICI) in treatment for various types of cancer, there are few reports which demonstrate ICI-associated cardiotoxicity across cancer types and agents are limited. This study estimates the frequency of cardiac adverse events within one year after ICI initiation. In addition, the overall survival of patients with ICI-associated cardiotoxicity are compared to those without cardiotoxicity after ICI use🔆
To view or add a comment, sign in
-
-
📢Today we share the #Review "Role of β-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma" 👏by Masahiro Morita, Naoshi Nishida, et al. 📌Find the full paper here: https://lnkd.in/dt_KUQmD Keywords: hepatocellular carcinoma; β-catenin activation; immune microenvironment
To view or add a comment, sign in
-
-
Adjuvant immunotherapy treatment on Merkel cell carcinoma? #Justnew Adjuvant therapy with nivolumab resulted in an absolute risk reduction of 9% (1-year DFS) and 10% (2-year DFS). Awaiting further data. #skincancer #merkelcellcarcinoma #immunotherapy #IO #oncoalert #cancer Reference: Lancet. 2023 Jul 11;S0140-6736(23)00769-9. doi: 10.1016/S0140-6736(23)00769-9
To view or add a comment, sign in
-
-
New antibody, mouse anti human CD196 Human CD196, also known as CCR6, is a chemokine receptor that is expressed on immature dendritic cells, B lymphocytes, and memory T cells. CCR6 binds CCL20, although members of the β defensin family also bind CCR6 with a lower affinity. In humans, CCR6 can function to mediate arrest of T cells on dermal endothelial cells and is highly expressed on T cells resident in both normal and psoriatic skin. CCR6 and/or CCL20 have been implicated in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Human T cells that are able to produce IL-17 express CCR6. It suggests that CCL20 and CCR6 have a role in inflammatory diseases by recruiting Th17 cells to target tissues. Format: CD196 Purified, CD196 PE Inquire us at orders@quantobio.com #QuantoBio #Monoclonalantibody #Flowcytometry #Biomarker #Cancer #CCR6 #chemokinereceptor
To view or add a comment, sign in
-
-
TIM3+VISTA+ macrophage subset that mediates resistance to anticancer, Immunotherapy and chemotherapy - Cell Stress and Immunity Lab #AntiCancer #Immunotherapy #Chemotherapy #Oncology #Cancer #Research #OncoDaily
TIM3+VISTA+ macrophage subset that mediates resistance to anticancer, Immunotherapy and chemotherapy -Cell Stress and Immunity Lab - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
Associate Professor of Pathology at Qatar University; Corresponding member of the Academy of Sciences and Arts of Bosnia and Herzegovina (ANUBiH); Editor in Chief, Biomolecules and Biomedicine (previously BJBMS)
Very important and clinically relevant study highlights why the tumor fraction of ctDNA measurement is essential for proper profiling and identification of predictive biomarkers for cancer patients.
Study evaluates the utility of circulating tumor DNA (ctDNA) tumor fraction (TF) in liquid biopsies (LBx) to distinguish between true negative results and false negatives, compared to tissue-based testing, in various cancers. Results indicate that when ctDNA TF is ≥1%, LBx has high concordance with tissue testing for detecting driver alterations, suggesting LBx alone may suffice for treatment decisions in these cases. Conversely, patients with lung cancer and negative LBx but ctDNA TF <1% often have drivers detected on subsequent tissue testing, highlighting the importance of reflex testing in such scenarios for prompt treatment initiation. Source: Clinical Cancer Research (Link to article in comments) Just out by our OncoAlert #LungCancer Faculty Christian Rolfo, MD, PhD, MBA,Dr.h.c. and team Russell Madison Lincoln Pasquina Yanmei Huang Ryon Graf, PhD Geoff Oxnard Hatim Husain Ping Umberto Malapelle Alessandro Russo
To view or add a comment, sign in
-
-
C-Level Innovator and Entrepreneur | Drug Development | Microbiologist and Immunologist | Microbiome | Biotechnology and Biomanufacturing
ILC2 either from autologous or heterologous sources exhibits direct anti-tumor effects against hematological cancer and solid tumors Zhenlong Li et al. Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell, 2024, doi:10.1016/j.cell.2023.12.015. Research reveals an immune cell that can attack cancerhttps://lnkd.in/gUAwR4wt
To view or add a comment, sign in
-
-
Insights to develop future immunotherapy strategies and enhance precision targeting with existing agents This work tries to understand immune cell surveillance and diverse immune evasion responses in tumor tissues. Using the Clinical Proteomic Tumor Analysis Consortium (CPTAC), we study over 1,000 tumors across ten cancer types. We identify seven distinct immune subtypes based on integrative learning of cell type compositions and pathway activities. See more at: https://lnkd.in/g_bckRpK
To view or add a comment, sign in
-